快速访问
文章信息
参考文献
[1]MILLER K D, SIEGEL R L, LIN C C, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436.
[2]赵文静, 杨之洵, 郑荣寿, 等. 2024美国癌症统计报告解读及中美癌症流行情况对比[J]. 肿瘤防治研究, 2024, 51(08): 630-641.
[3]BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[4]LEMJABBAR-ALAOUI H, HASSAN O U, YANG Y W, et al. Lung cancer: Biology and treatment options[J]. Biochim Biophys Acta, 2015, 1856(2): 189-210.
[5]WANG K, CHEN Q, SHAO Y Y, et al. Anticancer activities of TCM and their active components against tumor metastasis[J]. Biomed Pharmacother, 2021, 133: 111044.
[6]张浩杰, 孟园园, 杨延龙. 中医药治疗足癣临床研究进展[J]. 河北中医, 2025, 47(02): 345-347+352.
[7]王瑛兰, 崔翠翠, 刘元昆. 复方土槿皮搽剂治疗足癣[J]. 中国民间疗法, 2021, 29(01): 66.
[8]陶翠祥. 复方土槿皮酊的制备及质量控制和临床应用[J]. 内蒙古中医药, 2013, 32(01): 137+145.
[9]CHIU P, LEUNG L T, KO B C. Pseudolaric acids: isolation, bioactivity and synthetic studies[J]. Nat Prod Rep, 2010, 27(7): 1066-1083.
[10]LIU M L, WU Y, HUANG Q, et al. A Systematic Review of the Immune-Regulating and Anticancer Activities of Pseudolaric Acid B[J]. Front Pharmacol, 2017, 8: 394.
[11]YANG S P, YUE J M. Antifungal diterpenoids of Pseudolarix kaempferi, and their structure-activity relationship study[J]. Bioorg Med Chem, 2003, 11(21): 4577-4584.
[12]ZHANG Y L, LU R Z, YAN A L. Inhibition of ova fertilizability by pseudolaric acid B in hamster[J]. Zhongguo Yao Li Xue Bao, 1990, 11(1): 60-62.
[13]YAO G D, SHANG X Y, JIN Y X, et al. Activation of p53 contributes to pseudolaric acid B-induced senescence in human lung cancer cells in vitro[J]. Acta Pharmacol Sin, 2016, 37(7): 919-929.
[14]SUN Q, LI Y. The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway[J]. PLoS One, 2014, 9(9): e107830.
[15]ZHANG H, WU L, YANG L, et al. Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways[J]. Phytomedicine, 2019, 59: 152759.
[16]LI X, YANG J, LIU D, et al. Pseudolaric Acid B Inhibits Proliferation, Invasion and Epithelial-to-Mesenchymal Transition in Human Pancreatic Cancer Cell[J]. Yonsei Med J, 2018, 59(1): 20-27.
[17]JARRETT A M, SHAH A, BLOOM M J, et al. Mathematical models of tumor cell proliferation: A review of the literature[J]. Expert Rev Anticancer Ther, 2018, 18(12): 1271-1286.
[18]YIN Z, ZHANG J, CHEN L, et al. Pseudolaric Acid B Inhibits Proliferation, Invasion, and Angiogenesis in Esophageal Squamous Cell Carcinoma Through Regulating CD147[J]. Drug Des Devel Ther, 2020, 14: 4561-4573.
[19]WONG V K, CHIU P, CHUNG S S, et al. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo[J]. Clin Cancer Res, 2005, 11(16): 6002-6011.
[20]CASTEDO M, PERFETTINI J L, ROUHIER T, et al. Cell death by mitotic catastrophe: a molecular definition[J]. Oncogene, 2004, 23(16): 2825-2837.
[21]SCHMIDT M, BASTIANS H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs[J]. Drug Resist Updat, 2007, 10(4-5): 162-181.
[22]SARKAR T, MUKHERJEE A, CHATTOPADHYAY S, et al. Interaction of pseudolaric acid B with the colchicine site of tubulin[J]. Biochem Pharmacol, 2012, 84(4): 444-450.
[23]CHENG Z, LU X, FENG B. A review of research progress of antitumor drugs based on tubulin targets[J]. Transl Cancer Res, 2020, 9(6): 4020-4027.
[24]ROGALSKA A, MIŚKIEWICZ K, MARCZAK A. Inhibitors of microtubule polymerization- new natural compounds as potential anti-cancer drugs[J]. Postepy Hig Med Dosw (Online), 2015, 69: 571-585.
[25]WEN C, HUANG L, CHEN J, et al. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells[J]. Cancer Lett, 2016, 383(2): 295-308.
[26]YU J, LIU Y, GONG H, et al. Pseudolaric acid B inhibits proliferation in SW579 human thyroid squamous cell carcinoma[J]. Mol Med Rep, 2015, 12(5): 7195-7202.
[27]LI S, GUO L. Pseudolaric acid B induces G2/M arrest and inhibits invasion and migration in HepG2 hepatoma cells[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2018, 34(1): 59-64.
[28]GOLDAR S, KHANIANI M S, DERAKHSHAN S M, et al. Molecular mechanisms of apoptosis and roles in cancer development and treatment[J]. Asian Pac J Cancer Prev, 2015, 16(6): 2129-2144.
[29]PISTRITTO G, TRISCIUOGLIO D, CECI C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies[J]. Aging (Albany NY), 2016, 8(4): 603-619.
[30]GUAN D, LI C, LI Y, et al. Pseudolaric acid B inhibits PAX2 expression through Wnt signaling and induces BAX expression, therefore promoting apoptosis in HeLa cervical cancer cells[J]. J Gynecol Oncol, 2019, 30(5): e77.
[31]GONG X, LI D, LI N, et al. Pseudolaric acid B induces apoptosis via activation of c-Jun N-terminal kinase and caspase-3 in HeLa cells[J]. Exp Mol Med, 2004, 36(6): 551-556.
[32]YAO G, YANG L, HU Y, et al. ATM-p53 pathway causes G2/M arrest, but represses apoptosis in pseudolaric acid B-treated HeLa cells[J]. Arch Biochem Biophys, 2014, 558: 51-60.
[33]YAO G D, SHANG X Y, JIN Y X, et al. Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro[J]. Acta Pharmacol Sin, 2017, 38(10): 1401-1411.
[34]GUAN T, YANG Y. Role of pseudolaric acid B in A549 lung cancer cell proliferation and apoptosis[J]. Mol Med Rep, 2014, 9(1): 144-148.
[35]LI K S, LI P B, HE K, et al. Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis[J]. World J Gastroenterol, 2005, 11(48): 7555-7559.
[36]ZHAO D, LIU Z, DING J, et al. Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells[J]. Toxicol In Vitro, 2012, 26(4): 595-602.
[37]LUO D, LIU R, CHEN J, et al. Pseudolaric acid B suppresses NSCLC progression through the ROS/AMPK/mTOR/autophagy signalling pathway[J]. Biomed Pharmacother, 2024, 175: 116614.
[38]WIRAWAN E, VANDEN BERGHE T, LIPPENS S, et al. Autophagy: for better or for worse[J]. Cell Res, 2012, 22(1): 43-61.
[39]RUSSELL R C, GUAN K L. The multifaceted role of autophagy in cancer[J]. Embo j, 2022, 41(13): e110031.
[40]MATHEW R, KARANTZA-WADSWORTH V, WHITE E. Role of autophagy in cancer[J]. Nat Rev Cancer, 2007, 7(12): 961-967.
[41]YU J, QIAN H, LI Y, et al. Bcl-2 family proteins were involved in pseudolaric acid B-induced autophagy in murine fibrosarcoma L929 cells[J]. J Pharmacol Sci, 2008, 107(3): 295-302.
[42]YU J, QIAN H, LI Y, et al. Pseudolaric acid B induced cell cycle arrest, autophagy and senescence in murine fibrosarcoma l929 cell[J]. Int J Med Sci, 2013, 10(6): 707-718.
[43]YU J, LIU Y, GUO C, et al. Pseudolaric acid B activates autophagy in MCF-7 human breast cancer cells to prevent cell death[J]. Oncol Lett, 2016, 11(3): 1731-1737.
[44]WANG Y, LIU Y, WU Q, et al. Pseudolaric acid B induced autophagy, but not apoptosis, in MRC5 human fibroblast cells[J]. Oncol Lett, 2018, 15(1): 863-870.
[45]WOLF K, FRIEDL P. Molecular mechanisms of cancer cell invasion and plasticity[J]. Br J Dermatol, 2006, 154(Suppl 1): 11-15.
[46]FRIEDL P, WOLF K. Tumour-cell invasion and migration: diversity and escape mechanisms[J]. Nat Rev Cancer, 2003, 3(5): 362-374.
[47]JUSTUS C R, LEFLOE N, DIXON D A. In vitro cell migration and invasion assays[J]. J Vis Exp, 2014(88).
[48]MONDAL S, ADHIKARI N, BANERJEE S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview[J]. Eur J Med Chem, 2020, 194: 112260.
[49]HUNTER K W. Ezrin, a key component in tumor metastasis[J]. Trends Mol Med, 2004, 10(5): 201-204.
[50]ONDER T T, GUPTA P B, MANI S A, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways[J]. Cancer Res, 2008, 68(10): 3645-3654.
[51]VAN ROY F, BERX G. The cell-cell adhesion molecule E-cadherin[J]. Cell Mol Life Sci, 2008, 65(23): 3756-3788.
[52]WANG D, WANG J, CAO Y, et al. Pseudolaric acid B inhibits gastric cancer cell metastasis in vitro and in haematogenous dissemination model through PI3K/AKT, ERK1/2 and mitochondria-mediated apoptosis pathways[J]. Exp Cell Res, 2017, 352(1): 34-44.
[53]WANG D, CAO Y, ZHENG L, et al. Pseudolaric acid B induces endometrial cancer Ishikawa cell apoptosis and inhibits metastasis through AKT-GSK-3β and ERK1/2 signaling pathways[J]. Anticancer Drugs, 2017, 28(6): 603-612.
[54]STOCKWELL B R. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022, 185(14): 2401-2421.
[55]ZHAO L, ZHOU X, XIE F, et al. Ferroptosis in cancer and cancer immunotherapy[J]. Cancer Commun (Lond), 2022, 42(2): 88-116.
[56]WANG Z, DING Y, WANG X, et al. Pseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT[J]. Cancer Lett, 2018, 428: 21-33.
[57]MIAO Y, CHEN Y, XUE F, et al. Pseudolaric acid B triggers ferritinophagy and ferroptosis via upregulating NCOA4 in lung adenocarcinoma cells[J]. J Cancer Res Ther, 2023, 19(6): 1646-1653.
[58]FERRARA N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis[J]. Am J Physiol Cell Physiol, 2001, 280(6): C1358-C1366.
[59]GENSICKA M, GLOWKA M, SOCHAWSKI S. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity[J]. Curr Med Chem, 2015, 22(33): 3830-3847.
[60]AMINI A, MASOUMI MOGHADDAM S, MORRIS D L, et al. The critical role of vascular endothelial growth factor in tumor angiogenesis[J]. Curr Cancer Drug Targets, 2012, 12(1): 23-43.
[61]TAN W F, ZHANG X W, LI M H, et al. Pseudolaric acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect[J]. Eur J Pharmacol, 2004, 499(3): 219-228.
[62]LI M H, MIAO Z H, TAN W F, et al. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation[J]. Clin Cancer Res, 2004, 10(24): 8266-8274.
[63]DENG H, ZHANG L, ZHANG Y, et al. Design, synthesis, and evaluation of antitumor activity in Pseudolaric acid B Azole derivatives: Novel and potent angiogenesis inhibitor via regulation of the PI3K/AKT and MAPK mediated HIF-1/VEGF signaling pathway[J]. Eur J Med Chem, 2024, 278: 116813.
[64]TONG Y G, ZHANG X W, GENG M Y, et al. Pseudolaric acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin[J]. Mol Pharmacol, 2006, 69(4): 1226-1233.
[65]BUKOWSKI K, KCIUK M, KONTEK R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy[J]. Int J Mol Sci, 2020, 21(9).
[66]LI Y J, LEI Y H, YAO N, et al. Autophagy and multidrug resistance in cancer[J]. Chin J Cancer, 2017, 36(1): 52.
[67]WAGHRAY D, ZHANG Q. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment[J]. J Med Chem, 2018, 61(12): 5108-5121.
[68]YU F, WANG Q, ZHANG Z, et al. Pseudolaric acid B circumvents multidrug resistance phenotype in human gastric cancer SGC7901/ADR cells by downregulating Cox-2 and P-gp expression[J]. Cell Biochem Biophys, 2015, 71(1): 119-126.
版权与开放获取声明
作为一本开放获取的学术期刊，所有文章均遵循 Creative Commons Attribution 4.0 International License (CC BY 4.0) 协议发布，允许用户在署名原作者的前提下自由共享与再利用内容。所有文章均可免费供读者和机构阅读、下载、引用与传播，EWA Publishing 不会通过期刊的出版发行向读者或机构收取任何费用。